Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Cartalax vs KPV
An educational, source-based comparison of Cartalax and KPV — how each peptide works, what it's researched for, and what to know before going deeper.
Tripeptide bioregulator researched for cartilage and joint support.
A synthetic tripeptide (Ala-Glu-Asp) in the Khavinson short-peptide family. Research suggests gene-expression modulation in chondrocytes and fibroblasts, supporting extracellular matrix synthesis and reducing cartilage degradation markers.
- Osteoarthritis and cartilage repair
- Joint mobility in aging
- Tendon and ligament integrity
- • Preclinical and Russian clinical data only.
- • Not FDA-approved.
The C-terminal tripeptide (Lys-Pro-Val) of α-MSH. Research suggests anti-inflammatory effects via melanocortin pathways and intracellular NF-κB modulation — without the pigmentation effects of full-length α-MSH.
- Inflammatory bowel disease models
- Atopic dermatitis (topical research)
- Mast cell stabilization
- • Not FDA-approved.
- • Most evidence is preclinical.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Cartalax | Cartalax and chondrocyte gene expression | Bulletin of Experimental Biology and Medicine | 2015 | Modulated collagen type II and aggrecan expression in cultured chondrocytes. |
| KPV | KPV reduces colonic inflammation in IBD models | Gastroenterology | 2009 | Oral KPV nanoparticles reduced inflammatory markers in mouse colitis. |
Side-effect & safety grid
- Preclinical and Russian clinical data only.
- Not FDA-approved.
- Not FDA-approved.
- Most evidence is preclinical.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Cartalax vs KPV — Key differences
- Class: Cartalax is classified as Musculoskeletal · Bioregulator, while KPV is Gastrointestinal · Anti-inflammatory.
- Primary research focus: Cartalax — osteoarthritis and cartilage repair; KPV — inflammatory bowel disease models.
- Tag: Joint · Bioregulator vs Gut · Anti-inflammatory.